louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05846555: Optic Nerve Sheath Diameter in Urologic Surgery
Official title: Comparison of Optic Nerve Sheath Diameter and Cerebral Regional Oxygen Saturation in Urological Surgery While Lithotomy Position
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Urological Manifestations
Anesthesia
Keywords: optic nerve sheath diameter
lithotomy position
near infrared spectrometer
Lead sponsor: Gaziosmanpasa Research and Education Hospital
Sponsor class: OTHER_GOV
First posted: 2023-05-06
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Urologic Surgery Patients

Brief summary: The investigators aimed to determine intracranial pressure changes during spinal and general anesthesia by using optic nerve sheath diameter and near infrared spectrometer in urologic surgery patients in lithotomy position. Also the investigators plan to evaluate to measure intrathoracic pressure effects to intracranial pressure.

Detailed description: The patients will be divided into 2 groups as those who underwent general anesthesia and spinal anesthesia.Both groups at the specified times.

(The patient is supine for both groups before the start of the anesthesia procedure.) position T0, for group G, T1G 2 minutes after intubation, T1S 2 minutes after spinal anesthesia for group S, two T2, lithotomy 5 minutes after the lithotomy position for the group lithotomy to T3 30 minutes after the T4, T5 in PACU ) 60 minutes after optic nerve sheath diameter (OSC) values and lung assessment (LUS), cerebral cerebral palsy with Near-infrared spectroscopy (NIRS) oxygenation, mean arterial pressure, peripheral oxygen saturation, serum sodium, arterial carbon dioxide values and heart rate values will be recorded and significant statistical differences will be evaluated.

Eligibility criteria: Inclusion Criteria:

* ASA 1-2-3, patients
* over 18 years of age who will undergo urological surgery

Exclusion Criteria:

* Existing disease that causes an increase in intracranial pressure
* Patients with optic nerve pathology,
* Ophthalmologic diseases

Primary outcomes:
measure: intracranial pressure changes during Spinal and general anesthesia
timeFrame: position T0, for group G, T1G 2 minutes after intubation, T1S 2 minutes after spinal anesthesia for group S, two T2, lithotomy 5 minutes after the lithotomy position for the group lithotomy to T3 30 minutes after the T4, T5 in PACU ) 60 minutes after
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Gaziosmanpaşa TREH
state: Gaziosmanpaşa
city: Istanbul
country: Turkey
facility: Gaziosmanpaşa TREH
Study officials:
affiliation: gaziosmanpasa TREH
name: zuhal çavuş, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01656655: Effect of Post Traumatic Stress Disorder on Parenting
Official title: Parenting With and Without PTSD: The Effect of Attachment, Symptoms and Posttraumatic Growth
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Post Traumatic Stress Disorder
Keywords: ptsd, parenting
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
Collaborators: name: Hillel Yaffe Medical Center
First posted: 2012-08-03
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with ptsd

Brief summary: PTSD affects a wide variety of symptoms, some of which have been shown to disrupt family relationships. This study will examine some of the effects on parenting, from the perspective of the parent with PTSD.


Eligibility criteria: Inclusion Criteria:

* ptsd (PSS\>15) children under age 18

Exclusion Criteria:

* non ptsd (pss\<15) children under age 18

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
state: Choose a State
Study officials:
affiliation: Hadassah Medical Organization
name: rena Cooper, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00591955: Infected Elders in the Emergency Department: Outcomes and Processes of Care
Official title: Infected Elders in the Emergency Department: Outcomes and Processes of Care
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sepsis
Keywords: geriatric
sepsis
outcome assessment(healthcare)
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2008-01-11
Enrollment: 213
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 65 or older who present to the Emergency Department with signs that could be consistent with infection

Brief summary: The purpose of this study is to determine factors which predict a complicated hospital course and then to develop from these findings an Emergency Department guideline to assist in knowing who is at highest risk of elderly patients with infection presenting for care.

Detailed description: The study is looking at how closely physicians adhere to treatment guidelines in caring for elderly patients, and then to determine if there are differences in elderly patient disease symptoms that result in a failure to use guidelines. If this is known, physicians can then be aware of these differences and provide appropriate care.

Eligibility criteria: Inclusion Criteria:

* age 65 or older
* blood cultures ordered in the Emergency Department
* admitted to the hospital from the Emergency Department

Exclusion Criteria:

* age less than 65
* prisoners
* Patient unable to provide consent and no legally authorized representative available
* non-English speaking
* ED visit or admission in the last 7 days for the same condition
* primary evaluation by the trauma team

Primary outcomes:
measure: Complicated Clinical course
timeFrame: 0-30 days from ED visit
Secondary outcomes:
measure: Inadequate process of care
timeFrame: entire length of Emergency Department visit and hospitalization
Other outcomes:
Locations:
city: Columbus
country: United States
facility: The Ohio State University Medical Center
state: Ohio
Study officials:
affiliation: The Ohio State University Department of Emergency Medicine
name: Jeffrey M Caterino, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04098055: Effect of Insoles in Patients With Systemic Lupus Erythematosus
Official title: Effectiveness of Custom-made Foot Orthoses in Patients With Systemic Lupus Erythematous
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lupus Erythematosus, Systemic
Foot Orthoses
Musculoskeletal Pain
Keywords: Lupus Erythematosus, Systemic
Foot Orthoses
Foot
Pain
Lead sponsor: University of Seville
Sponsor class: OTHER
First posted: 2019-09-20
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Demonstrate that custom-made insoles improve painful symptomatology, health and foot function in subjects with SLE and podiatric involvement.


Eligibility criteria: Inclusion Criteria:

* 18 years or more.
* Medical diagnosis of LES.
* Foot involvement.

Exclusion Criteria:

* Treatment with foot orthoses.
* LES with acute symptomatic flare.
* Ulcers.
* Skin involvement.
* Neurological problems.
* Cognitive deterioration.
* Need for walking assistance.
* Refused to change footwear to use the foot orthoses.

Primary outcomes:
measure: 11-point Numeric Pain Rating Scale
timeFrame: 1 minute
measure: SF- 12 Quality of Life
timeFrame: 10 minutes
measure: Foot Function
timeFrame: 5 minutes
measure: Foot Disability
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Seville
country: Spain
facility: Department of Podiatry
Study officials:
References:
citation: Pipili C, Sfritzeri A, Cholongitas E. Deforming arthropathy in systemic lupus erythematosus. Eur J Intern Med. 2008 Nov;19(7):482-7. doi: 10.1016/j.ejim.2008.01.017. Epub 2008 Apr 1.
citation: Otter SJ, Kumar S, Gow P, Dalbeth N, Corkill M, Rohan M, Davies KA, Pankathelam S, Rome K. Patterns of foot complaints in systemic lupus erythematosus: a cross sectional survey. J Foot Ankle Res. 2016 Mar 22;9:10. doi: 10.1186/s13047-016-0143-8. eCollection 2016.
citation: Reina-Bueno M, Vazquez-Bautista MDC, Perez-Garcia S, Rosende-Bautista C, Saez-Diaz A, Munuera-Martinez PV. Effectiveness of custom-made foot orthoses in patients with rheumatoid arthritis: a randomized controlled trial. Clin Rehabil. 2019 Apr;33(4):661-669. doi: 10.1177/0269215518819118. Epub 2018 Dec 17.
citation: Reina-Bueno M, Vazquez-Bautista MDC, Palomo-Toucedo IC, Dominguez-Maldonado G, Castillo-Lopez JM, Ramos-Ortega J, Munuera-Martinez PV. Effectiveness of custom-made foot orthoses in patients with systemic lupus erythaematosus: protocol for a randomised controlled trial. BMJ Open. 2021 Mar 1;11(3):e042627. doi: 10.1136/bmjopen-2020-042627.
Clinical trial NCT03128255: Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.
Official title: I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thyroid Nodule
Thyroid Diseases
Thyroid Goitre
Keywords: Fusion
Hybrid Imaging
Mapping
Iodine
Ultrasound
Lead sponsor: Jena University Hospital
Sponsor class: OTHER
Collaborators: name: GE Healthcare
First posted: 2017-04-25
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Data of patients with unclear findings on regular thyroid work-up who had received additional I-124-PET/US in our institution.

Brief summary: Regular thyroid diagnostics versus augmented thyroid work-up with additional I-124 PET/US fusion for metabolic-sonographic nodule allocation in patients with benign thyroid diseases


Eligibility criteria: Inclusion Criteria:

* patients with thyroidal nodules,
* euthyroidism
* Uptake \>0,5% on Tc-99m-pertechnetate- scintigraphy

Exclusion Criteria:

* thyroid medications in the last 6 months
* Iodine exposition in the last 6 months
* thyroid surgery or radioiodine therapy

Primary outcomes:
measure: Metabolic-sonographic nodule allocation
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Jena
country: Germany
facility: University Hospital Jena
state: Thuringia
Study officials:
References:
Clinical trial NCT02608255: A Prospective Pilot Study to Evaluate a New Marker of Ischemia in Chest Pain Triage
Official title: A Prospective Pilot Study to Evaluate a New Marker of Ischemia in Chest Pain Triage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Coronary Syndrome
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2015-11-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: A Single-center prospective pilot study enrolling chest pain patients. CD 26 measurement will be performed and compared to troponin µs for early triage of these patients. This novel biomarker of myocardial ischemia (CD26) will be measured at the time of first medical contact (T0) and after 30 min simultaneously o troponin Ic.

All patients aged over 18 years with chest pain which may be related to acute coronary syndrome requiring pre hospital medical contact through the Emergency Medical Service.

Detailed description: First objectives: demonstrating the early positivity of CD26 compared to ultra-sensitive troponin.

Eligibility criteria: Inclusion Criteria:

* Subject with compatible symptoms with an acute coronary syndrome, for at least 15 minutes and not older than 3 hours (eg discomfort, tightness or chest pain, pain radiating to the left arm or two arms, pain in the jaw, pain in the back / neck / stomach, breathlessness , cold sweats, nausea / vomiting , dizziness )
* Man or woman,
* Patient Did not receive heparin or low molecular weight heparin (LMWH ) before the initial blood sample ,
* Patient Agreeing to participate in the study and who signed an informed consent

Exclusion Criteria:

* Minor or major patient trust
* Patient Not having signed informed consent (refusal , physical or mental disability ... )
* Patient Who received anticoagulation before carrying blood samples
* Patient With a progressive septic processes , neoplasia undergoing treatment, dialyzed kidney failure, a history of surgery or coronary angioplasty less than six months.
* Transplanted heart, renal or hepatic
* heart attack
* Subject Whose symptoms clearly eliminates acute coronary syndrome ( penetrating trauma, traumatic injury by crushing ... )
* Patient Died between the time of inclusion and arrival in the cardiology intensive care ( SIC )
* Patient Withdrawing consent under study

Primary outcomes:
measure: blood sample : dosage of CD26
timeFrame: 12 MONTHS
measure: blood sample: dosage of the copeptin
timeFrame: 12 months
measure: blood sample: dosage of troponin
timeFrame: 12 months
measure: blood sample : dosage of IMA
timeFrame: 12 months
measure: blood sample: dosage of adenosin
timeFrame: 12months
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique Hopitaux de Marseille
Study officials:
affiliation: AP HM
name: BONELLO laurent
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02137655: Recovery After Fast Track THA / TKA
Official title: Prospective Descripive Study of Subacute Function After Total Hip or Knee Arthroplasty
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hip and Knee Osteoarthritis
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Lundbeck Foundation
First posted: 2014-05-14
Enrollment: 112
Sex: ALL
Minimum age (years): 55
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with hip or knee osteoarthritis referred for total joint arthroplasty.

Brief summary: The development and implementation of "fast-track" principles in total knee and hip arthroplasty have resulted in early recovery and rehabilitation alongside a reduced length of hospital stay. This without a concomitant increase in morbidity or readmissions for medical or surgical complications and with reduced mortality. However, only little is known about function in the subacute period after arthroplasty, and there is a need for further data on physical and psychological functioning following discharge from hospital.This to ensure, that the positive results from the perioperative setting are carried forward in the subacute phase.

Detailed description: Data will be published in three papers:

1. "Physical function and related factors following discharge from THA and TKA" Luna IE, Kehlet H, Aasvang EK.
2. "Postoperative hypoxemia following fast-track hip and knee arthroplasty" Luna IE, Kehlet H, Aasvang EK.
3. "Cognitive dysfunction after fast-track hip- and knee arthroplasty - prevalence and related factors". Luna IE, Kehlet H, Aasvang EK.

Eligibility criteria: Inclusion Criteria:

* Primary total hip or knee arthroplasty
* Age 55 to 80 years

Exclusion Criteria:

* Deficient written or spoken danish
* Alcohol abuse (\>21 U per week)
* Immunocompromised
* Anticoagulant therapy
* ASA class 4-5
* Functional impairment from psychological or neurological disease
* Sleepapnea

Primary outcomes:
measure: Pain
timeFrame: 48 hours postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Gentofte
country: Denmark
facility: Gentofte hospital
state: Region hovedstaden
city: Vejle
country: Denmark
facility: Vejle Sygehus
state: Region syd
Study officials:
References:
Clinical trial NCT06952855: Observationa Study is a Prospective and Multi-institutional Observational Study.
Official title: Observational Study to Evaluate Effectiveness, Safety and Satisfaction Level of Zastaprazan (JAQBO®) Under Daily Treatment for Patients With Erosive Gastroesophageal Reflux Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Erosive Reflux Disease
Heartburn
Acid Regurgitation
Keywords: GERD
ERD
Lead sponsor: Jeil Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-05-01
Enrollment: 5536
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: GERD patients

Brief summary: This observational study is a prospective, multi-institutional non intervention study to examine the prescription patterns, corresponding treatment effects and safety in routine clinical practice for patients prescribed for the treatment of gastroesophageal reflux disease.

Detailed description: The present observational study is designed to check effect and safety for patients who have been prescribed JAQBO for the treatment of erosive gastroesophageal reflux disease.

Eligibility criteria: Inclusion Criteria:

1. An adult over 19 years of age
2. A person who voluntarily provides written informed consent

Exclusion Criteria:

1. A pregnant woman or a nursing woman
2. A person who is deemed unsuitable for the subject of the study

Primary outcomes:
measure: Change in GERD (heartburn, acid regurgitation) score in RDQ
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Goodbreath Medical Center
state: Gyeonggi-do
Study officials:
References:
Clinical trial NCT04017455: Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
Official title: Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Rectal Cancer
Keywords: short term immunotherapy
atezolizumab
bevacizumab
radiotherapy
Lead sponsor: The Netherlands Cancer Institute
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
First posted: 2019-07-12
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: single group, open label
Primary purpose: TREATMENT

Brief summary: In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab

Detailed description: 38 patients with resectable rectal cancer will be enrolled. All patients will be treated with radiotherapy followed by bevacizumab and atezolizumab.

Eligibility criteria: Inclusion Criteria:

* signed informed consent
* patients age 18 years and older
* histologically confirmed adenocarcinoma of the rectum
* intermediate risk rectal cancer or low risk distal rectal cancer

Exclusion Criteria:

* evidence of metastatic disease
* prior radiation therapy for disease under study
* prior treatment with CD137 agonists or immune checkpoint blockade therapies
* current or recent use of acetylsalicylic acid
* history of clinically significant cardiac or pulmonary dysfunction pregnancy or breastfeeding
* significant auto-immune disease

Primary outcomes:
measure: clinical complete and near-complete response rate
timeFrame: 12 weeks post-radiotherapy
Secondary outcomes:
measure: incidence of adverse events following treatment (safety)
timeFrame: untill 100 days after last patient last study drug
measure: local recurrence rate at 1 year follow-up
timeFrame: 1 year post-radiotherapy
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Marieke van de Belt
state: Noord-Holland
Study officials:
affiliation: Antoni van Leeuwenhoek
name: Myriam Chalabi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01066455: Cardiac Outcome Measures in Children With Muscular Dystrophy
Official title: PITT1109: Cardiac Outcome Measures in Children With Muscular Dystrophy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
Limb Girdle Muscular Dystrophy
Keywords: Cardiac
Muscular Dystrophy
Prospective
Pediatric
Echocardiogram
Lead sponsor: Cooperative International Neuromuscular Research Group
Sponsor class: NETWORK
Collaborators: name: National Institutes of Health (NIH)
First posted: 2010-02-10
Enrollment: 48
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 8 to 18 years old Confirmed diagnosis of Duchenne, Becker, or autosomal recessive limb-girdle muscular dystrophy (LGMD: 2C-2F and 2I)

Brief summary: The purpose of the research study is to evaluate different cardiac measures that are obtained by echocardiographic tests in patients with muscular dystrophy.

Detailed description: The research study will include 50 participants aged 8 to 18 years old (before 18th birthday) with Duchenne, Becker, or autosomal recessive limb-girdle (specifically: LGMD 2C-2F and 2I) muscular dystrophies.

Participants will be seen in one of five Cooperative International Neuromuscular Research Group (CINRG) centers located in the United States.

All study assessments will be completed in the same day and include reviewing past medical and surgical history, collecting vital signs, collecting cardiac measures through echocardiographic tests.

Eligibility criteria: Inclusion Criteria:

* Participants must be between the ages of 8 and 18 years old
* Confirmed diagnosis of muscular dystrophy (DMD, BMD, or LGMD 2C-2F and 2I)

Exclusion Criteria:

* Investigator assessment of inability to comply with protocol
* History of a congenital cardiac defect or other cardiac disease unrelated to muscular dystrophy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis
state: California
city: Washington
country: United States
facility: Children's National Medical Center
state: District of Columbia
city: St. Louis
country: United States
facility: Washington University St. Louis
state: Missouri
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
city: Houston
country: United States
facility: Texas Children's Hospital
state: Texas
Study officials:
References: